Healthcare - Biotechnology - NASDAQ - US
$ 3.8
-11.6 %
$ 122 M
Market Cap
-2.24
P/E
INCOME STATEMENT
0
REVENUE
-38.4 M
OPERATING INCOME
-37.9 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Candel Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 24 M |
| Gross Profit | -24 M |
| Operating Expenses | 14.4 M |
| Operating Income | -38.4 M |
| Other Expenses | -452 K |
| Net Income | -37.9 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| REVENUE | |||||
| Revenue | 0 | 0.1 | 0.1 | 0.1 | 0.1 |
| GROSS PROFIT | |||||
| Cost Of Revenue | 24.0 | 1.0 | 0.2 | 0 | 6.6 |
| Gross Profit | (24.0) | (0.9) | (0.1) | 0.1 | (6.5) |
| OPERATING INCOME | |||||
| Operating Expenses | 14.4 | 34.8 | 24.8 | 13.3 | 8.6 |
| Selling, General and Administrative Expenses | 14.4 | 14.1 | 10.7 | 5.2 | 2.6 |
| Research and Development Expenses | 24.5 | 20.8 | 15.2 | 8.8 | 6.6 |
| Operating Income | (38.4) | (34.7) | (25.7) | (13.8) | (9.0) |
| PRE-TAX INCOME | |||||
| Interest Income Expense | (2.6) | 0.5 | 53 K | 0 | 0 |
| Total Other Income | 0.5 | 15.9 | (10.4) | (3.9) | 0.8 |
| Pre-Tax Income | (37.9) | (18.8) | (36.1) | (17.7) | (8.2) |
| NET INCOME | |||||
| Tax Provision | 0 | (15.9) | 53 K | 4.5 | (0.2) |
| Net Income | (37.9) | (2.9) | (36.2) | (22.2) | (8.0) |
| EPS | 1.31 | 0.0994 | 1.26 | 0.76 | 0.27 |